NCT05604287 - Safety, Tolerability, and Pharmacokinetics of ID119031166M With the Exploration of Pharmacodynamic Effects | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 10, 2022

Primary Completion Date

April 12, 2024

Study Completion Date

April 12, 2024

Conditions

Healthy Participants

Interventions

DRUG

ID119031166M

The participants will receive a single oral dose of ID119031166M or once daily oral doses of ID119031166M for 14 days.

DRUG

Placebo

The participant will receive a oral dose of Placebo.

Trial Locations (1)

California Clinical trials medical group/PAREXEL, Glendale